Verrica Pharmaceuticals Inc.
VRCA Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$3.53
KIRA · Stoqly’s AI analyst, in plain words
- Verrica Pharmaceuticals Inc. had $35.6M of revenue in fiscal 2025, up 370.2% on the year before.
- Its operating margin was −34.2%, up 837.0 pts: of every 100 in sales, about −34 is left after running the business.
- Verrica Pharmaceuticals Inc. lost $17.9M in fiscal 2025.
- Free cash flow was −$17.6M in fiscal 2025, −49.5% of revenue.
- Verrica Pharmaceuticals Inc. has $29.1M more cash than debt.
Market cap
$75.2M
P/E
—
Revenue
$35.6M
Net income
−$17.9M
Free cash flow
−$17.6M
Operating margin
−34.2%
Verrica Pharmaceuticals Inc. in 30 seconds · fiscal 2025
Are sales growing?
+370.2%
Yes. Sales grew 370.2% last year.
Does it make a profit?
−50.3%
No. It lost money last year.
Does profit turn into cash?
−49.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Verrica Pharmaceuticals Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 11, 2026
- Legal name
- Verrica Pharmaceuticals Inc.
- CIK
- 0001660334
Verrica Pharmaceuticals Inc. · VRCA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $12.0M | $9.0M | $5.1M | $7.6M | $35.6M |
| Revenue growth | — | −24.7% | −43.3% | 47.7% | 370.2% |
| Gross margin | — | — | 90.2% | 65.6% | — |
| Operating margin | −257.6% | −235.8% | −1,283.4% | −871.3% | −34.2% |
| Net income | −$35.1M | −$24.5M | −$67.0M | −$76.6M | −$17.9M |
| Net margin | −292.3% | −271.1% | −1,307.5% | −1,012.1% | −50.3% |
| Diluted EPS | −$1.30 | −$0.72 | −$1.48 | −$14.78 | −$1.68 |
| Cash | |||||
| Cash from operations | −$27.6M | −$18.7M | −$38.6M | −$60.9M | −$17.6M |
| Capital expenditure | $0.9M | $0.3M | $0.4M | $0.0M | $0.0M |
| Free cash flow | −$28.5M | −$19.0M | −$38.9M | −$61.0M | −$17.6M |
| FCF margin | −237.2% | −209.8% | −759.9% | −805.6% | −49.5% |
| Share count change | 8.2% | 26.3% | 32.7% | −88.6% | 105.6% |
| Debt and strength | |||||
| Cash and short-term investments | $15.8M | $34.3M | $69.5M | $46.3M | $30.1M |
| Debt incl. finance leases | $41.7M | $0.0M | $44.3M | $32.1M | $1.0M |
| Shareholders' equity | $32.6M | $40.0M | $19.8M | −$9.9M | $24.7M |
| Current ratio | 1.6x | 11.3x | 4.6x | 1.8x | 2.6x |
| Interest coverage | −7.2x | −9.8x | −16.6x | −7.0x | −1.6x |
| Returns and quality | |||||
| Return on capital | −41.7% | −292.1% | — | — | — |
| Return on equity | −107.0% | −67.4% | −224.1% | −1,546.6% | −240.4% |
| Return on tangible equity | −107.6% | −61.2% | −339.0% | — | −72.3% |
| Piotroski F-score | 2 | 4 | 1 | 3 | 5 |
| Altman Z'' | −5.2 | −0.9 | −9.4 | −24.1 | −19.4 |
Insiders bought, 12 months
$18.2M
5 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Verrica Pharmaceuticals Inc. · VRCA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.53 a share, the company is worth $75.2M.
Source: SEC EDGAR XBRL filings (CIK 0001660334). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.